EGFR and neoplasm: However, in clinical practice, the status of EGFR mutation is usually determined by tissue-based analysis (42), which has a number of limitations, e.g., i) sampling bias due to tumor heterogeneous, ii) associated complications owing to invasive biopsies, iii) not rapid and expensive, and iv) failing to get reliable results due to the low quantity or quality of the tissue samples (43).